Edward B. Garon, MD, on Metastatic NSCLC: GEOMETRY mono-1 Trial of Capmatinib

May 13, 2020 By The ASCO Post Staff

Edward B. Garon, MD, of the University of California, Los Angeles, David Geffen School of Medicine, discusses results from a small study in METex14-mutated advanced non–small cell lung cancer and brain metastases. The trial suggested capmatinib showed antitumor activity in the brain, regardless of prior therapy, and a manageable safety profile (Abstract CT082).

Related Content